Bloomberg: Chinese Firms Seen Exploring Carveouts to Boost Value: ECM Watch
August 6, 2024
Some Hong Kong-listed biotechnology companies are exploring spinoff listings or joint-venture possibilities with foreign partners that could lead to initial public offerings elsewhere. O’Melveny partner Ke Geng said that those firms see themselves as undervalued in Hong Kong. “If those assets remain part of the Hong Kong-listed company, their valuation would be depressed,” he added.
Bloomberg subscribers can read the full article here.